Anna Gandini
Overview
Explore the profile of Anna Gandini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
47
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barbato L, Campelo M, Pigozzo S, Realdon N, Gandini A, Barbazza R, et al.
EJIFCC
. 2020 Apr;
31(1):15-20.
PMID: 32256285
Introduction: hemolysis is the primary cause of sample/test rejection by the laboratory. Case Report: A 10-year-old, admitted with an asthma attack in the emergency-room, medicated with albuterol sulphate (intravenous bronchodilator...
2.
La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, et al.
Cochrane Database Syst Rev
. 2016 Nov;
11:CD009333.
PMID: 27880972
Background: Interferons-beta (IFNs-beta) and glatiramer acetate (GA) were the first two disease-modifying therapies (DMTs) approved 20 years ago for the treatment of multiple sclerosis (MS). DMTs' prescription rates as first...
3.
La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, et al.
J Neurol Neurosurg Psychiatry
. 2015 Jan;
86(9):1016-20.
PMID: 25550414
Interferon β (INFβ) and glatiramer acetate (GA) are widely used in patients with relapsing-remitting multiple sclerosis (RRMS). However, it is still unclear whether they have different efficacy. We performed a...
4.
La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, et al.
Cochrane Database Syst Rev
. 2014 Jul;
(7):CD009333.
PMID: 25062935
Background: Interferons (IFNs)-beta and glatiramer acetate (GA) were the first two disease-modifying therapies (DMTs) approved 15 years ago for the treatment of multiple sclerosis (MS). DMTs prescription rates as first...
5.
Lora A, Cosentino U, Gandini A, Zocchetti C
Epidemiol Psichiatr Soc
. 2008 Mar;
16(4):330-8.
PMID: 18333429
Aims: The treatment of schizophrenic disorders is the most important challenge for community care. The analysis focuses on packages of care provided to 23.602 patients with a ICD-10 diagnosis of...
6.
Lora A, Bezzi R, Di Vietri R, Gandini A, Spinogatti F, Zocchetti C
Epidemiol Psichiatr Soc
. 2002 Sep;
11(2):100-15.
PMID: 12212462
Objective: The analysis aims to study the packages of care in the public Departments of Mental Health by diagnosis and service utilisation intensity. Design: Data on community, hospital and residential...